CGENCompugen LtdRunning, no new patients
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
Ovarian Cancer · Ovarian Cancer Recurrent
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 60 (planned)
- Started
- Jul 21, 2025
- Main results expected
- Mar 2027
- Fully finished
- Mar 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
To evaluate the effect of COM701 as a single agent on progression free survival when administered as a maintenance regimen in participants with relapsed PSOC
Measured over: From the date of randomization until the date of disease progression, or date of death from any cause whichever occurs first, assessed up to 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06888921 · record last updated 2026-10-06 · checked 2026-11-09 15:47 UTC